Extracellular vesicle

Where the papers sit

21 papers from the last 6 months study extracellular vesicle directly · updated from PubMed 12 Oct 2026

• Regenerative EV Therapies

  Cell-free vesicle therapy is moving toward engineered, primed and tissue-targeted products for inflammatory and degenerative injury. Stem-cell vesicles reprogram microglia, reduce neuronal apoptosis and autophagy, and improve nerve, cognitive, respiratory and joint outcomes. Plant-derived vesicles and engineered natural-killer vesicles broaden the source material, while hybrid hydrogels improve wound delivery. miRNA-mediated immune trafficking and chemokine regulation recur, but most evidence remains preclinical, apart from expanded-access COVID-19 analysis.

  9 papers · 42.9%

• Cancer EV Biomarkers and Therapy

  Cancer vesicle research is moving toward combined therapy, biomarker discovery and cell-specific detection. Fibroblast-derived vesicles promote pancreatic cancer through RAP1B/ANLN, while programmable tumor vesicles deliver immune-epigenetic treatment against colorectal metastasis. EpCAM-imprinted capture, glycosylation sensing and subpopulation-specific miRNA assays are expanding diagnostic readouts across gastric, pancreatic and other cancers. Dendritic-cell vesicles remain a proposed acellular therapeutic platform, with clinical translation still open.

  7 papers · 33.3%

• Aggressive Cancer EV Signatures

  Aggressive breast cancer research is linking extracellular-vesicle miRNA patterns with diagnosis and antitumor activity. Temperature-compensated optical microfibre gratings are being developed to improve triple-negative breast cancer detection. NFAT3-regulated vesicles produce a combinatorial miRNA signature associated with activity against aggressive cancers. Whether these signatures can guide treatment or outperform established biomarkers remains unresolved.

  2 papers · 9.5%

• Others — Vesicle Biology in Tissue Injury

  Tissue injury and remodeling are the shared focus, but applications range from treatment to biomarker discovery. Brain-derived vesicles deliver PRDX3 to reduce periodontal alveolar bone loss, while engineered membranes support vascularized periodontal regeneration. Cirrhosis studies instead use vesicle profiles to track thrombo-inflammatory, endothelial and tissue-remodeling changes. The cluster links vesicles with damaged tissues without establishing a common therapeutic direction.

  3 papers · 14.3%